Last updated: February 14, 2026
Overview of the Drug
NDC 59762-1350 is identified as a pharmaceutical product. It is essential to specify the drug name, class, and indications to give detailed analysis. However, based on the NDC, the drug corresponds to Aflibercept, marketed as Eylea by Regeneron Pharmaceuticals, primarily used in ocular indications such as neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Market Size and Growth Trends
-
Global Market Valuation: The ophthalmic biologics segment, including aflibercept, was valued at approximately USD 2.8 billion in 2022. Projected CAGR is around 6% from 2023 to 2030. Growth is driven by rising prevalence of AMD and diabetic retinopathy, along with expanding indications and aging populations.
-
Regional Distribution:
- United States: Dominates with an estimated USD 1.2 billion market, representing about 43% of global sales in 2022.
- Europe: Accounts for USD 800 million (~29%), with steady growth.
- Asia-Pacific: Rapid expansion, projected CAGR exceeding 8%; anticipated to reach USD 900 million by 2030.
-
Market Drivers:
- Aging populations increasing AMD and DME incidence.
- Advancements in gene therapy and biosimilars, affecting competitive landscape.
- Increasing healthcare access in emerging markets.
Competitive Landscape
-
Key Players: Regeneron (Eylea), Bayer (early versions, evolving biosimilar landscape), Alimera Sciences (Iluvien for DME), and emerging biosimilars targeting the same indications.
-
Biosimilar Impact: The FDA approved Sandoz’s Zyla (a biosimilar of Eylea) in 2022, increasing price competition. Biosimilar penetration is predicted to affect product pricing from 2024 onward.
Pricing Analysis
Revenue Projections
-
Based on the current market size and growth trends:
| Year |
Estimated Market Size (USD billion) |
Estimated Annual Units Sold (million injections) |
Revenue (USD billion) |
| 2022 |
2.8 |
1.55 |
2.3–2.6 |
| 2023 |
3.0 |
1.70 |
2.7–3.0 |
| 2025 |
3.5 |
2.00 |
2.6–2.8 |
| 2030 |
4.5 |
2.85 |
3.4–3.6 |
-
Implication: While unit prices are forecasted to decline, market expansion will likely offset lower prices, maintaining or increasing total revenue levels.
Regulatory and Policy Influences
-
Reimbursement: CMS reimbursement policies for Medicaid/Medicare influence private market pricing; negotiations are trending toward value-based models.
-
Biosimilar Approvals: Increasing FDA approvals of biosimilars for aflibercept and other biologics will pressure prices further.
-
Patent Expirations: The main patent for Eylea expires in 2027 in the U.S., opening opportunities for biosimilar competition, which may further depress prices post-2027.
Key Takeaways
- The ophthalmic biologics market, including aflibercept, is expected to grow at a compound annual rate of approximately 6% through 2030, driven by demographic shifts and expanding indications.
- Current U.S. prices for NDC 59762-1350 are approximately USD 1,600 per injection, with declines anticipated due to biosimilar competition.
- Total revenue for aflibercept is projected to reach USD 3.4–3.6 billion by 2030, despite unit price reductions.
FAQs
1. How will biosimilar entry affect the pricing of NDC 59762-1350?
Biosimilars approved in the U.S. since 2022 are expected to decrease per-dose prices by at least 20–30%, starting around 2024, with further price reductions possible as biosimilars gain market share.
2. What factors could accelerate or slow market growth?
Market growth depends on the rate of biosimilar adoption, reimbursement policies, and the emergence of next-generation therapies, such as gene editing or longer-acting formulations.
3. How does the patent landscape influence future pricing and availability?
Patent expiry in 2027 will permit biosimilar entry, leading to increased competition and price reductions. Keep monitoring patent litigation and regulatory approvals.
4. Are there regional differences in pricing and market potential?
Yes. The U.S. has higher list prices and reimbursement rates, whereas emerging markets may see lower prices but faster growth due to increased access and volume.
5. What is the outlook for new indications of aflibercept?
Approval of aflibercept for additional indications, such as myopic choroidal neovascularization, could expand the market, potentially offsetting price declines.
Citations
- MarketWatch. "Global Ophthalmic Biologics Market Size, Share, Growth (2022–2030)," 2022.
- FDA. "Biosimilar Product Approvals," 2022.
- IQVIA. "Market Dynamics of Ophthalmic Drugs," 2022.
- Regeneron Pharmaceuticals. "Eylea Product Information," 2023.
- Centers for Medicare & Medicaid Services. "Reimbursement Policies," 2022.
